Editas Medicine Inc $ 31.62 0.14 (0.44%)
Volume:
1,026,249
Avg Vol (1m):
1,231,932
Market Cap $:
1.96 Bil
Enterprise Value $:
1.58 Bil
P/E (TTM):
0.00
P/B:
7.38
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 15.27 | ||
| Equity-to-Asset | 0.5 | ||
| Debt-to-Equity | 0.12 | ||
| Debt-to-EBITDA | -0.21 | ||
| Piotroski F-Score | 1 | ||
| Altman Z-Score | 3.79 | ||
| Beneish M-Score | -3.86 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -646.16 | ||
| Net Margin % | -588.05 | ||
| ROE % | -63.65 | ||
| ROA % | -34.15 | ||
| ROC (Joel Greenblatt) % | -425.48 | ||
| 3-Year Revenue Growth Rate | 29.8 | ||
| 3-Year EBITDA Growth Rate | 6 | ||
| 3-Year EPS without NRI Growth Rate | 3.9 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 7.38 | ||
| PS Ratio | 68.17 | ||
| EV-to-EBIT | -11.66 | ||
| EV-to-EBITDA | -11.91 | ||
| EV-to-Revenue | 65.17 | ||
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.17 | ||
| Days Sales Outstanding | 27.65 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.9 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 7.39 | ||
| Earnings Yield (Greenblatt) % | -8.59 |